Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1987 1
1992 1
1993 2
1994 1
1995 4
1996 1
1997 5
1998 4
1999 2
2000 1
2002 2
2003 2
2004 3
2005 7
2006 3
2007 2
2008 3
2009 2
2010 2
2011 1
2012 2
2013 3
2014 1
2015 8
2016 2
2017 5
2018 7
2019 12
2020 8
2021 11
2022 10
Text availability
Article attribute
Article type
Publication date

Search Results

101 results
Results by year
Filters applied: . Clear all
Page 1
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP. Tolaney SM, et al. Among authors: overmoyer ba. N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281. N Engl J Med. 2015. PMID: 25564897 Free PMC article. Clinical Trial.
Inflammatory Breast Cancer: a Separate Entity.
Rosenbluth JM, Overmoyer BA. Rosenbluth JM, et al. Among authors: overmoyer ba. Curr Oncol Rep. 2019 Aug 15;21(10):86. doi: 10.1007/s11912-019-0842-y. Curr Oncol Rep. 2019. PMID: 31414257 Review.
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP. Tolaney SM, et al. Among authors: overmoyer b. J Clin Oncol. 2019 Aug 1;37(22):1868-1875. doi: 10.1200/JCO.19.00066. Epub 2019 Apr 2. J Clin Oncol. 2019. PMID: 30939096 Free PMC article. Clinical Trial.
Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial.
Tolaney SM, Barroso-Sousa R, Keenan T, Li T, Trippa L, Vaz-Luis I, Wulf G, Spring L, Sinclair NF, Andrews C, Pittenger J, Richardson ET 3rd, Dillon D, Lin NU, Overmoyer B, Partridge AH, Van Allen E, Mittendorf EA, Winer EP, Krop IE. Tolaney SM, et al. Among authors: overmoyer b. JAMA Oncol. 2020 Oct 1;6(10):1598-1605. doi: 10.1001/jamaoncol.2020.3524. JAMA Oncol. 2020. PMID: 32880602 Free PMC article. Clinical Trial.
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.
Brastianos PK, Strickland MR, Lee EQ, Wang N, Cohen JV, Chukwueke U, Forst DA, Eichler A, Overmoyer B, Lin NU, Chen WY, Bardia A, Juric D, Dagogo-Jack I, White MD, Dietrich J, Nayyar N, Kim AE, Alvarez-Breckenridge C, Mahar M, Mora JL, Nahed BV, Jones PS, Shih HA, Gerstner ER, Giobbie-Hurder A, Carter SL, Oh K, Cahill DP, Sullivan RJ. Brastianos PK, et al. Among authors: overmoyer b. Nat Commun. 2021 Oct 12;12(1):5954. doi: 10.1038/s41467-021-25859-y. Nat Commun. 2021. PMID: 34642329 Free PMC article. Clinical Trial.
Breast cancer screening.
Overmoyer B. Overmoyer B. Med Clin North Am. 1999 Nov;83(6):1443-66, vi-vii. doi: 10.1016/s0025-7125(05)70174-7. Med Clin North Am. 1999. PMID: 10584602 Review.
Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research.
Jagsi R, Mason G, Overmoyer BA, Woodward WA, Badve S, Schneider RJ, Lang JE, Alpaugh M, Williams KP, Vaught D, Smith A, Smith K, Miller KD; Susan G. Komen-IBCRF IBC Collaborative in partnership with the Milburn Foundation. Jagsi R, et al. Among authors: overmoyer ba. Breast Cancer Res Treat. 2022 Apr;192(2):235-243. doi: 10.1007/s10549-021-06434-x. Epub 2022 Jan 1. Breast Cancer Res Treat. 2022. PMID: 34973083 Free PMC article. Review.
Aggressive Subsets of Metastatic Triple Negative Breast Cancer.
Singh J, Asad S, Zhang Y, Nock W, Adams E, Damicis A, Ramaswamy B, Williams N, Parsons HA, Adalsteinsson VA, Winer EP, Lin NU, Partridge AH, Overmoyer B, Stover DG. Singh J, et al. Among authors: overmoyer b. Clin Breast Cancer. 2020 Feb;20(1):e20-e26. doi: 10.1016/j.clbc.2019.06.012. Epub 2019 Jul 31. Clin Breast Cancer. 2020. PMID: 31631016
Vocal fold paralysis on positron emission tomography-CT.
Ma C, Frosch ZA, Overmoyer B, Cooper AZ. Ma C, et al. Among authors: overmoyer b. Thorax. 2018 Jan;73(1):97-98. doi: 10.1136/thoraxjnl-2016-209261. Epub 2017 Jul 17. Thorax. 2018. PMID: 28717033 No abstract available.
101 results